^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
EGFR EXON 19 DELETION OR L858R MUTATIONS….Progression on erlotinib (± ramucirumab or bevacizumab), afatinib, gefitinib, or dacomitinib….SUBSEQUENT THERAPY...Continue erlotinib (± ramucirumab or bevacizumab) or afatinib or gefitinib or dacomitinib (if T790M-)
Evidence Level:
Sensitive: B - Late Trials
Title:

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases

Published date:
02/08/2023
Excerpt:
This was an open-label, parallel, phase 3 randomized clinical trial (GAP BRAIN) conducted in 6 centers in China. The main eligibility criteria included histologically or cytologically confirmed NSCLC with EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R mutation)...In this randomized clinical trial, gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS compared with gefitinib alone in patients with untreated EGFR-mutant NSCLC brain metastases...
Secondary therapy:
Chemotherapy
DOI:
10.1001/jamanetworkopen.2022.55050
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

Published date:
05/16/2018
Excerpt:
Pts with newly diagnosed stage III/IV/ recurrent NSCLC harboring an EGFR activating mutations (exon 19 deletion or exon 21 L858R) were randomized...GCP demonstrated significantly better PFS compared to G….Additional OS analysis (G:101 events vs GCP:83 events) revealed that median survival time of GCP was much longer than that of G (52.2 months vs 38.8 months, HR:0.695, p = 0.013).
Secondary therapy:
carboplatin + pemetrexed
DOI:
10.1200/JCO.2018.36.15_suppl.9005
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

Excerpt:
Pts with newly diagnosed stage III/IV/recurrent NSCLC harboring EGFR activating mutations (exon 19 deletion or exon 21 L858R) were randomized 1:1 to G 250 mg PO QD or GCP (G 250mg PO QD combined with carboplatin AUC 5 + pemetrexed 500mg/m2, every 3 weeks)....Although there was no difference in PFS2 between the arms, additional OS analysis (G 101 events vs GCP 83 events) revealed that median survival time of GCP was much longer than that of G (52.2 months vs 38.8 months, HR: 0.695, p = 0.013)....NEJ009 was the first phase III study which evaluated the efficacy of a combination of EGFR-TKI and platinum doublet chemotherapy in untreated advanced NSCLC pts with EGFR mutations.
Secondary therapy:
carboplatin + pemetrexed
DOI:
10.1093/annonc/mdy292.005
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Excerpt:
First-line gefitinib for patients with advanced non–small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
DOI:
10.1056/NEJMoa0909530
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Excerpt:
...Tumors with common EGFR mutations (19del or L858R) 3....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Excerpt:
...- Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial

Published date:
08/08/2023
Excerpt:
This was an open-label, single arm, multi-center phase II trial that included patients aged 19 or older with sensitizing EGFR mutations and stage III NSCLC who had received platinum-based CCRT. Participants were treated with Gefitinib (250mg daily) up to 12 months....53.5% (8/15) of the patients had L858R point mutation and 40% (6/15) of the patients had 19 deletion….Overall response rate was 66.67% (10/15) and disease control rate was 93.33% (14/15).
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Published date:
11/24/2022
Excerpt:
In this study, tumor tissues were collected from 101 patients with stage II/III resectable NSCLC with an EGFR mutation (57 patients were treated with gefitinib and 44 were treated with chemotherapy) in the ADJUVANT-CTONG1104 trial…use of Vβ20-1Jβ2-3 specifically for EGFR exon 19 del or Vβ9Jβ2-1 specifically for EGFR exon 21 mutation (L858R), and these were significantly associated with favorable overall survival (OS) for NSCLC patients harboring EGFR exon 19 del or exon 21 L858R, particularly in the adjuvant gefitinib setting...high abundance Vβ20-1Jβ2-3 or Vβ9Jβ2-1 may be an immune biomarker for guiding adjuvant gefitinib decisions for NSCLC patients harboring EGFR exon 19 del or EGFR exon 21 L858R.
DOI:
10.1007/s00262-022-03330-1
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study

Published date:
11/22/2022
Excerpt:
All patients were administered a first-generation EGFR-TKI (icotinib 125 mg tid or gefitinib 250 mg qd, orally)....The PFS of subgroups in number of metastases >5 vs. <5 and EGFR mutation L858R vs. 19-del were 11.13 months vs. 16.33 months (HR 0.45, 95% CI (0.23–0.91), p = 0.016) and 13.43 months vs. 26.69 months (HR 0.23, 95% CI (0.12–0.46), p = 0.0017), respectively (Figure 3)....early-phase SBRT for the primary lung tumor combined with EGFR-TKI followed by RT may be an alternative choice for advanced NSCLC harboring the EGFR mutation.
DOI:
https://doi.org/10.3390/life12121954
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Published date:
09/05/2022
Excerpt:
Among the 60 patients, 52 patients (86.7%) had exon 19 deletion or L858R mutation, with 49 patients (81.7%) receiving gefitinib as the first-line EGFR TKI. The median PFS and OS from the initiation of EGFR TKI were 10.4 months (95% confidence interval [CI], 7.4–13.2) and 21.3 months (95% CI, 13.4–28.8), respectively.
DOI:
https://doi.org/10.1007/s00432-022-04287-5
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P59.10 - A Sneak Peak in the Future World of EGFR Mutations: ML Based PFS Differences Between Del 19 and L858R

Published date:
08/18/2021
Excerpt:
413 patients of stage IV EGFR mutant NSCLC were analysed...Median PFS for each drug according to mutation is depicted in Table 1....Del19 and L858R mutations differ with respect to prognosis and therapeutics. In our population, del19 cases were more commonly male, and depicted a better PFS on 1st line TKI when compared to L858R positive cases (commonly female).
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

Published date:
10/07/2020
Excerpt:
...EGFR mutation-positive NSCLC received first-generation (1G, gefitinib or erlotinib) or 2G EGFR-TKI (afatinib) as the first-line (1L) systemic therapy....The objective response rate (ORR) for the 1L EGFR-TKI was 63.3%. The median progression-free survivals (PFSs) were 8.6 months (95% CI: 3.8-13.5), 11.7 months (95% CI: 6.6-16.7), 7.7 months (95% CI: 4.9-17.4), and 5.0 months (95% CI: 3.7-6.1) for major uncommon EGFR mutation (G719X, L861Q), compound mutation with major EGFR mutation (Del 19 or EGFR exon 21 p.L858R), other compound mutation, and other uncommon mutations, respectively.
DOI:
10.3390/biology9100326
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1395P - Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC?

Published date:
09/14/2020
Excerpt:
We analyzed EGFR-mutant advanced NSCLC patients treated with first-line gefitinib, erlotinib or afatinib from Jan 2013 to Dec 2016….Of the 931 patients treated with first-line EGFR-TKI other than osimertinib, 140 (15.0%) patients were LTRs; gefitinib (n=85, 60.7%), erlotinib (n=22, 15.7 %), and afatinib (n=33, 23.6%), respectively...Patients with recurrent disease (OR 0.40, p<0.001), Exon 19 deletion (OR 0.58, p=0.007) and without wet pleura (OR 3.11, p<0.001), bone (OR 1.93, p=0.003), CNS (OR 1.69, p=0.018) or other extrathoracic organ (OR 7.09, p=0.001) metastases were associated with LTRs.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study

Published date:
04/29/2020
Excerpt:
...patients with operable stage II-IIIA NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation were enrolled.... ORR, the primary endpoint, was 54.5% (95% confidence interval [CI], 37.7-70.7), and the rate of MPR was 24.2% (95% CI, 11.9-40.4)....Neoadjuvant therapy with gefitinib in patients with stage II-IIIA NSCLC is safe and may be a viable treatment for patients whose tumors have EGFR mutations.
DOI:
10.1016/j.jtcvs.2020.02.131
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

Excerpt:
Predefined subgroup analysis showed that PC-G produced favorable HR (0.20, 95% CI 0.05–0.75; P = 0.017) for patients with EGFR mutations (exons 19/21) compared with PC with regard to PFS...In patients with EGFR mutations (exons 19/21), the ORR was 76.9% for the PC-G arm and 50% for the PC arm (P = 0.13).
Secondary therapy:
pemetrexed
DOI:
10.4161/cbt.28874
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

Excerpt:
Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation.
DOI:
10.1158/1078-0432.CCR-06-0462
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Excerpt:
All patients had activating EGFR mutations; 20 (54%) had an exon 19 deletion mutation and 15 (41%) had the exon 21 point mutation L858R. All patients had responded clinically to either gefitinib (n=5) or erlotinib (n= 32).
DOI:
10.1126/scitranslmed.3002003
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report

Published date:
02/05/2021
Excerpt:
The patient was diagnosed with stage IV NSCLC (T2aN3M1)...An EGFR deletion was detected in exon 19….The patient was treated with gefitinib (250 mg/d) and traditional herbal medicine, modified Bojungikki-tang (BJIKT)….A partial response was achieved, but after 3 months severe papulopustular skin rashes developed and became aggravated with time. Thus, the gefitinib dose was reduced. However, the PFS has been maintained for approximately 78 months.
DOI:
10.1097/MD.0000000000024292